ReviewAmerican journal of clinical dermatology2020
Generalized Pustular Psoriasis: Clinical Management and Update on Autoinflammatory Aspects.
Review in American journal of clinical dermatology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it, 58 citations in OpenAlex.
- The 2021 EULAR/American College of Rheumatology Points to Consider for Diagnosis, Management and Monitoring of the Interleukin-1 Mediated Autoinflammatory Diseases: Cryopyrin-Associated Periodic Syndromes, Tumour Necrosis Factor Receptor-Associated Periodic Syndrome, Mevalonate Kinase Deficiency, and Deficiency of the Interleukin-1 Receptor Antagonist.Arthritis & rheumatology (Hoboken, N.J.) · 2022Pooled it
- Clinical differentiation between acute generalized exanthematous pustulosis and generalized pustular psoriasis: A multi-center study.Chinese medical journal · 2026Article
- Economic Burden of Generalized Pustular Psoriasis: A Population-based Register Study in Finland.Acta dermato-venereologica · 2026Article
- Epidemiology, clinical characteristics, flares and mortality of generalized pustular psoriasis: a nationwide register study in Finland.Skin health and disease · 2025Article
- Updated genetic background of generalized pustular psoriasis as an autoinflammatory keratinization disease.The Journal of dermatology · 2025Review
- Case Report: Acute generalized exanthematous pustulosis with psoriasis successfully treated with Secukinumab.Frontiers in immunology · 2025Article
- Diseases categorized as autoinflammatory keratinization diseases (AiKDs), and their pathologies and treatments.Nagoya journal of medical science · 2024Review
- Successful Treatment of Pediatric Generalized Pustular Psoriasis (GPP) with Spesolimab: 5 Case Reports and Evaluations of Circulating IL-36 Levels.Journal of inflammation research · 2024Article
- Comparative Efficacy and Safety of Ustekinumab and Secukinumab in the Treatment of Generalized Pustular Psoriasis: A 48-Week Retrospective Cohort Study with Genetic Background Analysis.Journal of inflammation research · 2024Article
- Treatment Strategies in Neutrophilic Dermatoses: A Comprehensive Review.International journal of molecular sciences · 2023Review
- The update of treatment strategies in pediatrics with generalized pustular psoriasis in China.Pediatric investigation · 2023Review
- Review
- Current Status, Issues and Future Prospects of Personalized Medicine for Each Disease.Journal of personalized medicine · 2022Review
- Acute Generalized Pustular Psoriasis Developed Resistance to Adalimumab Was Successfully Treated with Narrowband Ultraviolet B and Acitretin: A Case Report.Clinical, cosmetic and investigational dermatology · 2022Article
- Clinical Course and Characteristics of Generalized Pustular Psoriasis.American journal of clinical dermatology · 2022Review
- The Prevalence and Disease Characteristics of Generalized Pustular Psoriasis.American journal of clinical dermatology · 2022Review
- Pustular Psoriasis: A Narrative Review of Recent Developments in Pathophysiology and Therapeutic Options.Dermatology and therapy · 2021Review
- Patient characteristics and burden of disease in Japanese patients with generalized pustular psoriasis: Results from the Medical Data Vision claims database.The Journal of dermatology · 2021Article
- Generalized Pustular Psoriasis: Divergence of Innate and Adaptive Immunity.International journal of molecular sciences · 2021Review
- A Novel Evaluation System of Psoriasis Curative Effect Based on Bayesian Maximum Entropy Weight Self-Learning and Extended Set Pair Analysis.Evidence-based complementary and alternative medicine : eCAM · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Generalized pustular psoriasis (GPP) is a chronic, systemic inflammatory disease accompanied by high fever and general malaise. Diffuse erythema and swelling of the extremities occur, with multiple sterile pustules all over the body in GPP patients. GPP often relapses over the lifetime and can be life-threatening. Recent discoveries of the underlying molecular genetic basis of many cases of this disorder have provided major advances to clinicians and researchers towards an understanding of the pathomechanism of GPP. However, the therapeutic management of GPP still faces many challenges and much uncertainty, and an evidence-based review summarizing the available clinical data on the management of this heterogeneous disease is needed. The present review addresses challenges regarding the precise clinical diagnosis and evaluation of clinical symptoms in GPP. In addition, we update and briefly summarize the current understanding of molecular pathomechanisms behind GPP as an autoinflammatory keratinization disease. Recent publications have clarified the genetic backgrounds of patients with GPP and ethnic differences in predisposing factors. Although there are ethnic differences in the prevalences of these pathogenic alleles, from recent reports, at most 60.5% (IL36RN), 5.9% (CARD14), and 10.8% (AP1S3) of GPP patients have the mutations/variations of these genes. All the reported biologics studied seemed effective and relatively well tolerated. Although it is difficult to evaluate therapeutic efficacy from studies on just a few cases, recent findings suggest that biologics can be a useful, powerful tool for controlling skin and systemic inflammation in GPP and for improving the quality of life of GPP patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.